Adult intracranial malignant hemangiopericytoma
diseaseOn this page
Also known as adult intracranial anaplastic hemangiopericytomaadult intracranial solitary fibrous tumor/hemangiopericytoma, grade 3adult malignant intracranial hemangiopericytomacentral nervous system solitary fibrous tumor/hemangiopericytoma, grade 3malignant adult intracranial hemangiopericytoma
Summary
Adult intracranial malignant hemangiopericytoma (MONDO:0003857) is a disease and 2 clinical trials. Top therapeutic interventions include gadobenate dimeglumine, gadobutrol, and gadopentetate dimeglumine. A subtype of hemangiopericytoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 2
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | adult intracranial malignant hemangiopericytoma |
| Mondo ID | MONDO:0003857 |
| DOID | DOID:6333 |
| NCIT | C9183 |
| UMLS | C1334558 |
| MedGen | 235288 |
| GARD | 0027653 |
| Is cancer (heuristic) | no |
Also known as: adult intracranial anaplastic hemangiopericytoma · adult intracranial solitary fibrous tumor/hemangiopericytoma, grade 3 · adult malignant intracranial hemangiopericytoma · central nervous system solitary fibrous tumor/hemangiopericytoma, grade 3 · malignant adult intracranial hemangiopericytoma
Disease family
This is a subtype of hemangiopericytoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › pericytic neoplasm › hemangiopericytic tumor › hemangiopericytoma › adult intracranial malignant hemangiopericytoma
Related subtypes (7): kidney hemangiopericytoma, meninges hemangiopericytoma, breast hemangiopericytoma, retroperitoneal hemangiopericytoma, heart malignant hemangiopericytoma, hemangiopericytoma, malignant, hemangiopericytoma of skin
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01119599 | PHASE1 | COMPLETED | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma |
| NCT02967380 | Not specified | TERMINATED | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| GADOBENATE DIMEGLUMINE | 4 | 1 |
| GADOBUTROL | 4 | 1 |
| GADOPENTETATE DIMEGLUMINE | 4 | 1 |
| CHEMBL4228794 | 0 | 1 |